

# CYBO VanEck Bionic Engineering UCITS ETF

# VanEck®

31 March 2024

## Fund Details

|                           |                                                                |
|---------------------------|----------------------------------------------------------------|
| Base Currency             | USD                                                            |
| Inception Date            | 02 December 2022                                               |
| Domicile                  | Ireland                                                        |
| Net Assets                | USD 6.4M                                                       |
| Shares Outstanding        | 290,000                                                        |
| Total Expense Ratio       | 0.55%                                                          |
| Product Structure         | Physical (Full Replication)                                    |
| UCITS Compliant           | Yes                                                            |
| Rebalance Frequency       | Quarterly                                                      |
| Distribution Frequency    | None                                                           |
| Income Treatment          | Reinvestment                                                   |
| Swiss Valor               | --                                                             |
| ISA Eligibility           | Yes                                                            |
| SIPP Available            | Yes                                                            |
| Countries of Registration | AT, CH, DE, DK, ES, FI, FR, IE, IT, LU, NL, NO, PL, PT, SE, UK |

## Index Information

|                     |                           |
|---------------------|---------------------------|
| Index Provider      | MarketVector Indexes GmbH |
| Index Type          | Total Return Net          |
| Currency            | USD                       |
| Inception Date      | 06 Dec 2021               |
| Rebalance Frequency | Quarterly                 |
| Bloomberg Ticker    | MVBIONTR                  |
| Reuters Ticker      | .MVBIONTR                 |

## Fund Data

|                       |           |
|-----------------------|-----------|
| Number of Holdings    | 25        |
| Price/Earnings Ratio* | 41.12     |
| Price/Book Ratio*     | 4.47      |
| Weighted Avg. MCap    | USD 42.9B |

\* Last 12 Months

## Country Breakdown

|                |        |
|----------------|--------|
| United States  | 78.71% |
| Switzerland    | 8.09%  |
| Australia      | 4.57%  |
| United Kingdom | 3.07%  |
| Italy          | 2.25%  |
| Denmark        | 1.85%  |
| Other/Cash     | 1.45%  |

## Fund Description

The VanEck Bionic Engineering UCITS ETF (CYBO) is a UCITS-compliant exchange-traded fund that invests in a portfolio of equity securities with the aim of providing investment returns that closely track the performance of the MVIS® Global Bionic Healthcare ESG Index.

The MVIS® The MVIS Global Bionic Healthcare ESG Index is a global index that tracks the performance of the largest and most liquid companies in medical/dental or vision-related implants, bioprinting, or prosthesis.

## Performance History\* (%)

| Month End as of 31 Mar 2024 | 1 MO* | 3 MO* | YTD* | 1 YR | 3 YR  | 5 YR | 10 YR | INCEPTION |
|-----------------------------|-------|-------|------|------|-------|------|-------|-----------|
| ETF                         | 6.30  | 7.21  | 7.21 | 3.90 | --    | --   | --    | 7.38      |
| MVBIONTR (Index)            | 6.34  | 7.35  | 7.35 | 4.33 | -0.81 | --   | --    | 7.85      |

Past performance does not predict future returns.

Performance quoted represents past performance. Current performance may be lower or higher than average annual returns shown. Discrete performance shows 12 month performance to the most recent Quarter end for each of the last 5yrs where available. E.g. '1st year' shows the most recent of these 12-month periods and '2nd year' shows the previous 12 month period and so on.

Performance data for VanEck ETFs is displayed on a Net Asset Value basis, in Base Currency terms, with net income reinvested, net of fees. Brokerage or transaction fees will apply.

## Top 10 Holdings

|                             |         |
|-----------------------------|---------|
| EDWARDS LIFESCIENCES CORP   | 10.55%  |
| DEXCOM INC                  | 10.12%  |
| MEDTRONIC PLC               | 9.94%   |
| STRYKER CORP                | 9.83%   |
| ZIMMER BIOMET HOLDINGS INC  | 7.14%   |
| COCHLEAR LTD                | 4.57%   |
| SONOVA HOLDING AG           | 4.39%   |
| STRAUMANN HOLDING AG        | 3.70%   |
| INSULET CORP                | 3.53%   |
| INSPIRE MEDICAL SYSTEMS INC | 3.19%   |
| SUBTOTAL - TOP 10           | 66.96%  |
| REMAINING HOLDINGS          | 32.88%  |
| OTHER/CASH                  | 0.16%   |
| TOTAL                       | 100.00% |

For a complete up-to-date listing of Fund holdings, please visit [www.vaneck.com](http://www.vaneck.com)



# CYBO VanEck Bionic Engineering UCITS ETF



## Trading Information

31 March 2024

| EXCHANGE               | TRADING CURRENCY | ISIN         | EXCHANGE TICKER | BLOOMBERG TICKER | REUTERS TICKER | SEDOL   | IOPV SYMBOL |
|------------------------|------------------|--------------|-----------------|------------------|----------------|---------|-------------|
| LONDON STOCK EXCHANGE  | USD              | IE0005TF9619 | CYBO            | CYBO LN          | CYBO.L         | BMTPNY4 | CYBOUSIV    |
| LONDON STOCK EXCHANGE  | GBP              | IE0005TF9619 | CYBG            | CYBG LN          | VVCYBG.L       | BMTPPH1 | --          |
| SIX Swiss Exchange CHF | CHF              | IE0005TF9619 | CYBO            | CYBO SE          | CYBO.S         | BMTPL5  | --          |
| BORSA ITALIANA         | EUR              | IE0005TF9619 | CYBO            | CYBO IM          | CYBO.MI        | BMTPPK4 | CYBOUSIV    |

## Key Risks

**Liquidity Risk:** It exists when a particular financial instrument is difficult to purchase or sell. If the relevant market is illiquid, it may not be possible to initiate a transaction or liquidate a position at an advantageous or reasonable price or at all. This is a main risk factor of a Bionic ETF.

**Equity Market Risk:** The prices of the securities in the Fund are subject to the risks associated with investing in the securities market, including general economic conditions and sudden and unpredictable drops in value. An investment in a Bionic ETF may lose money.

**Industry or Sector Concentration Risk:** The Fund's assets may be concentrated in one or more particular sectors or industries. A Bionic ETF may be subject to the risk that economic, political or other conditions that have a negative effect on the relevant sectors or industries will negatively impact the Fund's performance to a greater extent than if the Fund's assets were invested in a wider variety of sectors or industries.

For more information on risks, please see the "Risk Factors" section of the relevant Fund's prospectus, available on [www.vaneck.com](http://www.vaneck.com).

## IMPORTANT INFORMATION

This is a marketing communication. Please refer to the prospectus of the UCITS and to the KID before making any final investment decisions.

This information originates from VanEck (Europe) GmbH, which has been appointed as distributor of VanEck products in Europe by the Management Company VanEck Asset Management B.V., a UCITS Management Company incorporated under Dutch law and registered with the Dutch Authority for the Financial Markets (AFM). VanEck (Europe) GmbH, with registered address at Kreuznacher Str. 30, 60486 Frankfurt, Germany, is a financial services provider regulated by the Federal Financial Supervisory Authority in Germany (BaFin). The information is intended only to provide general and preliminary information to investors and shall not be construed as investment, legal or tax advice. VanEck (Europe) GmbH and its associated and affiliated companies (together "VanEck") assume no liability with regards to any investment, divestment or retention decision taken by the investor on the basis of this information. Information herein may change at any time; current data may differ from data quoted. Information provided by third party sources is believed to be reliable and have not been independently verified for accuracy or completeness and cannot be guaranteed. Brokerage or transaction fees may apply.

VanEck Asset Management B.V., the management company of VanEck Bionic Engineering UCITS ETF (the "ETF"), a sub-fund of VanEck UCITS ETFs plc, is a UCITS management company incorporated under Dutch law registered with the Dutch Authority for the Financial Markets (AFM). The ETF is registered with the Central Bank of Ireland, passively managed and tracks an equity index. Investing in the ETF should be interpreted as acquiring shares of the ETF and not the underlying assets.

Investors must read the sales prospectus and key investor information before investing in a fund. These are available in English and the KIDs in certain other languages as applicable and can be obtained free of charge at [www.vaneck.com](http://www.vaneck.com) or from the Management Company.

MVIS® Global Bionic Healthcare ESG Index is the exclusive property of MarketVector Indexes GmbH (a wholly owned subsidiary of Van Eck Associates Corporation), which has contracted with Solactive AG to maintain and calculate the Index. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards MarketVector Indexes GmbH ("MarketVector"), Solactive AG has no obligation to point out errors in the Index to third parties. The VanEck Bionic Engineering UCITS ETF (the "ETF") is not sponsored, endorsed, sold or promoted by MarketVector and MarketVector makes no representation regarding the advisability of investing in the ETF.

It is not possible to invest directly in an index.

All performance information is based on historical data and does not predict future returns.

Note: no guarantee can be provided that the fund will attain its objective. Investing is subject to risk, including the possible loss of principal.

No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission of VanEck.

The IOPV is calculated by S&P Global Ltd.

© VanEck (Europe) GmbH